Standout Papers

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an inter... 2018 2026 2020 2023 294
  1. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study (2018)
    Noopur Raje, Evangelos Terpos et al. The Lancet Oncology

Immediate Impact

52 standout
Sub-graph 1 of 22

Citing Papers

Screening for Osteoporosis to Prevent Fractures
2025 Standout
Recent Advances in 3D Printing of Smart Scaffolds for Bone Tissue Engineering and Regeneration
2024 Standout
2 intermediate papers

Works of Paul Cheng being referenced

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
2018 Standout

Author Peers

Author Last Decade Papers Cites
Paul Cheng 390 200 115 11 469
Evangelos Eleftherakis-Papaiakovou 420 225 150 10 532
Danielle E. Green 144 70 92 14 519
Marise Weil 188 229 247 10 574
Maria Rell‐Bakalarska 102 141 137 16 501
Nicola Lang 288 358 259 10 563
R. Blanco 271 168 46 11 448
Stephen Jarrett 71 137 87 9 562
Paavo Halonen 174 88 118 16 455
Judy Faust 166 214 218 14 483
Evelyn Loyer 279 35 145 11 475

All Works

Loading papers...

Rankless by CCL
2026